He 2020.

Methods	Study design: Randomised clinical trial Study duration: January 2017 to December 2018 Duration of follow‐up: 2 years Setting: Hospital
Participants	Number of participants: 72 Inclusion criteria: Diagnosed as HCC; age > 30 Age (mean ± SD, range ): TACE + RFA: 52.41 ± 5.85 years; TACE alone: 52.39 ± 5.97 years Male (n/total): TACE + RFA: 22/36; TACE alone: 20/36
Interventions	TACE + RFA group (n = 36): TACE: TACE comprised of hepatic arterial infusion chemotherapy and hepatic artery embolisation Chemotherapeutic drugs: 5‐fluorouracil 500 mg and oxaliplatin 50 mg RFA: US‐guided Control group (n = 36): TACE comprised of hepatic arterial infusion chemotherapy and hepatic artery embolisation Chemotherapeutic drugs: 5‐fluorouracil 500 mg and oxaliplatin 50 mg
Outcomes	Tumour response: measured by contrast‐enhanced CT at 2 weeks after treatment Survival rates: measured at 2 years after treatment Adverse events
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.